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Abstract 
Glioblastoma multiforme, an aggressive malignant tumor, continues to be amongst the 
most fatal disorders in medicine despite many therapeutic techniques and drug discoveries.  
Malignant brain tumor cells’ ability to invade surrounding brain parenchyma is the main reason 
for treatment failure and recurrence.  Traditional chemotherapy methods have found difficulty 
accessing the brain due to the blood-brain barrier, while irradiation techniques cause damaging 
effects on normal regions of the brain.  New forms of gene therapy have been found to 
eliminate tumor cells, while sparing healthy brain tissue; however, with no efficient delivery 
mechanism gene therapy has been unable to access a large amount of tumor cells to eliminate 
the tumor mass and prevent the likelihood of recurrence.  Local delivery of gene therapy has 
introduced a new method that looks to solve this problem, by delivering therapy directly to the 
brain tissue.  One method of local delivery is convection-enhanced delivery (CED) of poly(lactic-
co-glycolic acid (PLGA) nanoparticles, a biocompatible polymer material.  Using a catheter and 
pump, this intracranial drug delivery method allows for drug-loaded nanoparticles to be 
released directly into brain tissue in a bulk flow of fluid.  This method bypasses the blood-brain 
barrier and has a large distribution volume which has direct access to the tumor mass. 
 The efficacy of CED of siRNA nanoparticles on suppressing gene expression in tumor 
cells was studied in both in vitro experiments and in vivo rat models.  Fisher 344 rats were used 
as the animal model and 9L gliosarcoma cells, a highly aggressive malignant tumor, labeled with 
enhanced green fluorescent protein (EGFP) were the tumor source.  Small interfering RNA 
targeting the EGFP gene (siEGFP) were encapsulated into PLGA nanoparticles and used as a 
gene therapy.  Our study shows that siEGFP nanoparticles are capable of causing in vitro and in 
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vivo gene expression reductions of up to 50 and 60%, respectively.  When 9L cells were exposed 
to small interfering epidermal growth factor receptor (siEGFR), which targets the EGFR gene, in 
vitro growth suppression was observed that reduced 9L cell growth by 89% compared to the 
untreated control.  These gene knockdown results shown in this thesis suggest that siRNA-
loaded PLGA nanoparticles provide a great potential means for treating tumors. 
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Introduction 
Each year in the United States nearly 16,000 people are diagnosed with primary brain 
tumors.  Sixty percent of the brain tumors diagnosed in the United States are gliomas.  Gliomas 
are a heterogenous mix of neoplastic astrocytes.  Amongst these gliomas, glioblastoma 
multiforme (GBM) is the most common malignant glial tumor accounting for 12-15% of all 
intracranial neoplasms.  This neoplasm is often found in the subcortical white matter of the 
cerebral hemispheres.  In the United States and Europe, the incidence of GBM is 2-3 cases per 
100,000 people (1). 
There are two forms of Glioblastoma multiforme, primary and secondary.  Primary GBM 
is more prevalent (60% of cases) and consists of a de novo neoplasm that has no 
histopathologic evidence of a precursor lesion.  This type of lesion tends to present in patients 
over 50 years old.  Secondary glioblastoma multiforme often occurs in patients under 45 years 
old and forms from a slow progression of either a low grade astrocytoma or anaplastic 
astrocytoma.  This progression can take anywhere from one to ten years (2). 
 The etiology of GBM tumors varies widely.  Some of the genetic abnormalities seen in 
GBM tumors consist of 1) Loss of heterozygosity on the chromosomal arm 10q, 2) mutation in 
the tumor suppressor gene p53, 3) mutations in the epidermal growth factor receptor gene, 
which controls cell proliferation, 4) overexpression of the MDM2 gene, 5) overexpression of the 
platelet-derived growth factor-alpha gene (PDGF-α), which acts as a major growth factor for 
glial cells, and 6) mutation of the PTEN gene which encodes a tyrosine phosphatase that turns 
off signaling pathways.  Other mutations that are present in the most malignant forms of GBM 
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tumors are the MMAC1-E1 gene mutation, MAGE-E1 gene mutation, and NRP/B-A nuclear-
restricted protein mutation (2). 
Mean survival for GBM patients is inversely correlated with age.  Glioblastoma 
multiforme is slightly more common in whites and has a male-to-female ratio of 3:2.  Without 
treatment patients suffering from GBM will die in 3 months.  Those undergoing the standard 
treatment of surgical resection, radiation therapy, and chemotherapy have a median survival of 
9 months, with about 10% percent of these patients surviving for up to two years (1).   
Treatment options 
Glioblastoma multiforme remains a difficult tumor to cure.  Despite what is known 
about the gene mutations of the tumor, multiple challenges remain.  Current treatment aims at 
improving the quality of life of a patient with the standard care consisting of tumor resection 
followed by a combination of chemotherapy with temozolamide and radiation therapy.  
However these treatments have their limitations.  Poor tumor cell drug uptake, drug 
metabolism within the cell, and the degree of tumor cell sensitivity to a drug all limit the 
effectiveness of chemotherapies (1).  Surgical resection is often limited depending on the 
tumor’s location and the eloquence of the brain region.  In addition, the infiltrative nature of 
GBM tumors causes the majority of resections to be incomplete which allows infiltrative tumor 
cells to reform tumor within the near proximity of the resected site (3). 
Available chemotherapies have provided modest prolongation of survival and have been 
the focus of many laboratories.  Temozolomide, the current standard, has shown some 
promise.  A phase III randomized study showed that low-dose temozolomide used along with 
radiation therapy followed by six additional months of temozolomide showed a statistically 
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significant extended survival length of 14.6 months compared to 12.1 months with radiation 
therapy alone.  Another phase III randomized study looked at the implantation of FDA approved 
Gliadel wafers (polymer wafers with carmustine) into the tumor resected area of the brain and 
found prolongation of survival of 13.9 months compared to 11.6 months in the control group 
that received only radiation therapy (2). 
The Blood Brain Barrier and Brain tumor treatment 
In addition to tumor insensitivity and invasiveness, many chemotherapies are 
unsuccessful at treating central nervous system (CNS) disorders because of their inability to 
cross the blood brain barrier (BBB).  This is a specialized system of capillary endothelial cells 
that creates a semi-permeable barrier that protects the brain from noxious substances while 
still transporting essential nutrients to the brain.  The BBB is composed of an inner layer of 
endothelial cells with tight junctions, a basement membrane, pericytes, and astrocytes.  This 
serves as both a physical barrier and a biochemical barrier that is able to express peptidases 
that aid in effluxing drugs from the endothelial capillary cells back into the blood stream.  Small 
molecules that are less than 400 Da and have a high lipid solubility are two characteristics that 
have been shown to allow for transport across the BBB.  Some regions of the CNS, known as 
circumventricular organs, provide areas where the BBB is absent and the capillary system 
consists of fenestrated endothelial cells.  Areas such as the choroid plexus, pineal gland, 
neurohypophysis, area postrema are a few examples of this (4). 
In order to make chemotherapies effective once introduced into circulation, the BBB 
must be accounted for and several methods of drug delivery have had to deal with this issue.   
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Intravenous drug delivery allows for the administration of large amounts of drug into 
the blood circulation and avoids the first-pass metabolism.  However, intravenous 
administration of therapeutic drugs would result in little accumulation of the drug in the brain 
as a result of ineffective penetration across the BBB, as well as rapid metabolism of the drug in 
the plasma, and non-specific binding to plasma proteins (4). 
 Intraarterial administration of drugs has also been used as a method to access the brain.  
This method allows for a drug to enter brain vasculature prior to entering peripheral tissue 
which bypasses first pass metabolism.  It is believed that drugs travel arterially into the choroid 
plexus epithelium, then are transferred into the cerebral spinal fluid (CSF).  Often BBB 
disrupting agents such as bradykinin and mannitol can be used intraarterially to enhance the 
delivery of drugs to the brain, however, the amount of drug that reaches the brain is difficult to 
determine with this method (4). 
The intranasal route allows a drug to reach the brain by traveling through the nasal 
mucosa.  In this instance, the drug travels from the submucosa of the nose into the CSF.  This 
method is non-invasive and bypasses first-pass metabolism and the BBB completely.  The 
permeability of the nasal epithelium allows for the uptake of drugs tranasally into the brain and 
allows for the delivery of micro and macromolecules.  Intranasal delivery allows for self-
administration of small doses without the need of any modifications of the drug, such as 
coupling to a carrier.  Limitations of this method include damage and irritation to the nasal 
mucosa, rapid clearance of the drug via mucocilia in the nasal cavity, and interruption of drug 
transport secondary to nasal congestion (4). 
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 Another method used to completely bypass the BBB is through direct delivery of the 
therapeutics into the CSF of the CNS.  This method allows for higher concentrations of drug into 
the brain, avoids systemic exposure toxicities, and maintains the drug for a longer period of 
time within the brain.  This method can produce variable results depending on where the drug 
site of puncture is located, rate of drug clearance, CSF production rate, and the drug diffusion 
rate (4). 
 Intraparenchymal delivery allows for drugs to be injected as a bolus or an infusion 
through catheters or microparticles.  Bolus injection of a drug into the brain causes slow 
movement within the parenchyma due to limited diffusion in the brain.  Large amounts of drug 
must be used in order to overcome diffusion limitations to allow for adequate concentrations 
of the drug to be available to the surrounding parenchyma.  In an attempt to overcome 
diffusion issues, infusion of a drug using convection enhanced delivery (CED) distributes the 
drug to a wide area of brain tissue (4).   
Convection Enhanced Delivery 
CED is a method that was developed to overcome the diffusion limitation posed by the 
brain.  CED applies an external force to induce fluid convection within the brain.  Small 
catheters are placed several centimeters into the brain and are used to deliver a therapeutic via 
a pump.  High pressures are used to produce convective flow.  CED provides larger distribution 
volumes when compared to bolus injections.  It also provides long infusion times and is a viable 
method of delivering gene therapy, chemotherapy, and immune therapy.  Problems with this 
procedure are related to its invasiveness and drug distribution limitations that result from the 
anatomical environment.  These limits include backflow and occlusions of the catheter as well 
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as high intracranial pressures from the catheter infusion.  Small air bubbles can form from the 
infusion and cause damage to brain tissue.  The distribution of drug delivery is also 
unpredictable.  The white matter tracks of the brain provide highly conductive routes for the 
infused drug.  With this high conductivity and the backflow in the catheter, much of the drug 
delivered by CED will not be able to diffuse throughout the brain parenchyma.  In addition, 
perivascular spaces within the brain as well as the wound track of the injection or the space 
underneath the scalp can collect the infused drug during delivery shifting it away from its 
target.  These factors make it difficult to determine if the infused drug is a consistent 
concentration throughout its distributive space and may also lead to edema (3). 
 A recent phase III clinical study compared Gliadel to CED delivery of IL-13PE38QQR in 
patients who had failed conventional treatment for GBM tumors (surgery, radiotherapy, and 
chemotherapy).  The study showed that there was no significant difference in patient outcome 
with the median survival following tumor recurrence with the Gliadel and CED being 36.4 weeks 
and 35.3 weeks, respectively (5). A follow up paper suggested that imprecise catheter 
placement may have resulted in an absence of benefit in the CED exposed patient population 
(6). 
Compared to bolus injections, CED maintains drug distribution and concentration over a 
longer duration.  Alam et al. looked at the delivery of cytosine arabinoside, an antimetabolic 
agent used as a chemotherapy, and showed that CED provides for intraparenchymal 
concentrations that are 100 times greater than intranasal delivery and 1000 to 10,000 times 
greater than intravenous delivery (4). 
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 Implantable devices that provide controlled release of a drug within the brain are also 
used to provide direct drug delivery to the brain.  These implants are made of either 
biodegradable or non-biodegradable material and often encapsulate the drug.  They are placed 
into the brain where they release the drug for a predetermined duration.   One type of 
implantable device is the osmotic pump with refillable reservoirs that distributes drugs via a 
catheter. 
 For the purposes of this thesis, most of the focus will be on biodegradable, and more 
specifically polymer implants that are often used to deliver drugs to tumors.  These devices are 
constructed in the form of either wafers or nanoparticles and offer continued release of drugs 
from a degrading polymer. (4). 
 Wafer polymers, such as Gliadel, are polyanhydride wafers that contain the 
chemotherapeutic agent carmustine (BCNU).  This device has been FDA approved in the U.S. for 
implantation for new and recurrent Glioblastoma tumors.  Following the resection of a tumor 
these wafers can be inserted into the resected tumor cavity where they release the 
chemotherapy at a controlled rate that is proportional to the degradation rate of the specific 
polymer.  The tumor is exposed to 113 times the concentration of BCNU with Gliadel than 
would be achieved with systemic administration of the drug (7).  The localized chemotherapy 
provided by the wafers prevents a patient from being exposed to the high levels of radiation 
therapy that can weaken the immune system (3). 
 Although wafer polymers provide a controlled release system that is capable of 
sustained release for long durations of time, local penetration of the drug is often restricted by 
diffusion.  The drug’s low diffusion coefficient as well as the extracellular matrix (ECM) of the 
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brain, which presents small pore sizes, and the local environment of the tumor further limit the 
diffusive abilities of a drug.  In addition, many drugs have high rates of elimination.  The stated 
limitations cause a given drug to travel a minimal distance from its starting locus before 
degrading.  For the wafer polymer, the drug distribution is confined proximally to the wafer 
while the invasive tumor cells extend beyond this distance.  One way to bypass this issue is by 
using a polymer delivery system that is capable of navigating through the pores of the ECM in 
order to provide better diffusion throughout the brain (3).  Nanoparticles provide a smaller 
delivery vector that may be capable of greater distributive properties. 
Nanoparticles 
 Nanoparticles have become a popular mode of drug delivery to tumors in recent years.   
With their small size, controlled release capabilities, and the ability to modify the carriers to 
target selected molecules and receptors, nanoparticles present a new means for tumor 
therapy.  Nanoparticles can be used via direct infusion into the brain or by endcytotic 
mechanisms that allow them to cross the BBB (4).  They can be either nondegradable or 
biodegradable.  The nondegradable nanoparticles function by releasing drug from the 
nanoparticle matrix which then diffuses into the brain.  Biodegradable drug release is 
determined by the degradation of the polymer matrix in addition to the diffusion of the drug.  
Biodegradable polymers can be combined to form copolymers that modify the degradation and 
release pattern of the nanoparticle.  Properly designed nanoparticles have the capability of 
sustained drug delivery for several days to years.   Alterations can also be made to the polymer 
composition to affect release rate and longevity of a drug.  Unlike biodegradable wafers, 
nanoparticles have the ability to completely erode and be cleared from the body.  The 
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degradation of the nanoparticles occurs via hydrolysis, utilizing the large amounts of water in 
the human body.  Nanoparticles are also advantageous to their polymer wafer counterparts 
because the particles are able to be delivered less invasively to the brain via a burr hole and 
catheter (3). 
 Polymer constructs can be altered in order to maximize the release of a drug.  For 
example, the popularly used poly[bis(p-carboxyphenoxy)] propane-sebacic acid (p(CPP-SA)) is 
hydrolytically unstable when combined with the drug 4-hydroperoxycyclophosphamide (4HC), 
however, fatty acid dimer copolymers with 4HC provide the advantage of stability over the 
p(CPP-SA).    
 Another type of biodegradable polymer that has often been used in local drug delivery is 
the polylactic-coglycolic acid (PLGA) copolymer, which is a polymer matrix composed of lactide 
and glycolide polymers.  PLGA is a hydrophobic polymers whose monomer components are 
biocompatible.   This biomaterial has been used to make both nanoparticles and wafers and 
provides the ability to modify the characteristics of these particles that alter size and drug 
release.  Studies dealing with the characterization of nanoparticles have shown that smaller 
particles, 20nm in diameter or smaller, show more diffusion within the brain than larger 
particles, greater than 40nm.  Surface characteristics can also play a role in volume distribution.  
Mamot et al showed that particles with neutral or negative charge or that are coated with 
bovine serum albumin (BSA) or poly(ethylene glycol) (PEG) are able to maximize distribution 
volume, whereas positive charge has restricted diffusion. (3) 
 Combining CED with nanoparticles theoretically improves the delivery of drug to the 
brain.  The encapsulation of the drug within the nanoparticle prevents drug reflux which 
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improves delivery and helps prevent wound dehiscence.  Encapsulated drugs can also allow for 
shorter infusion times using CED.  This would cause smaller volumes of infusates and reduce the 
risk of edema and inflammation.  However, combining CED and nanoparticles may also present 
problems.  The polymer nanoparticles have to be large enough to deliver a relevant dose, 
however small enough to diffuse sufficiently throughout the parenchyma (3). 
Small Interfering RNA nanoparticles 
 In addition to CED, other modifications can be made to polymer nanoparticles to help 
improve therapy.  One of these alterations includes using small interfering RNA (siRNA) as the 
drug therapeutic.  RNA interference is a sequence specific gene silencing application which 
utilizes a 21-25 base pair double stranded RNA nucleotide sequence, known as siRNA.  The 
siRNA are integrated into RNA induced silencing complex (RISC) in the cytosol of the cell.  The 
RISC complex uses the antisense strand of the siRNA to bind to the complementary messenger 
RNA (mRNA) strand in the cell.  This initiates the initial cleavage and degradation of the specific 
mRNA sequences (8).   
 When preparing siRNA as a therapeutic for tumors, multiple steps must be taken.  First 
the siRNA must target mRNA whose downregulation would suppress growth or is integral to the 
disease process.  The siRNA must then be placed in a delivery complex that is capable of 
stability within an in vivo environment.  Finally the siRNA complex must be efficiently delivered 
to the brain or tumor site in order to effectively knockdown gene expression (8). 
 Some limitations that are involved with naked siRNA include early extracellular 
degradation in the serum, often having a half-life of a few minutes to one hour.  Some solutions 
that have tried to improve the stability of siRNA include chemical modifications that alter the 
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sugar backbone of the siRNA molecule.  In addition, polymer or lipid encapsulation have been 
shown to protect the siRNA from early degradation.   Naked siRNA also has a relatively large 
molecular weight of around 13 kDA and an anionic charge, both which makes it impossible to 
diffuse freely across the cell membrane.  Certain solutions to this problem include conjugating 
the siRNA to cell penetrating peptides (CPPs) or cholesterol.  Encapsulation of the siRNA with a 
polymer will also allow for endocytosis of the siRNA/polymer complex into the cell. (8) 
 Although siRNA are beneficial for their specificity in targeting genes, other issues with 
this type of therapy include nonspecific mRNA binding that can occur through partial mismatch 
or binding of the sense strand to the mRNA.   This nonspecific binding may cause interferon 
directed inflammation, toxicity to the cell, and unintended effects on the gene target.  Chemical 
modifications to the siRNA including annealing of the guide strand to an additional strand can 
prevent non-specific effects. (8) 
 The limited success with the delivery of naked siRNA makes it necessary to develop a 
delivery vehicle that is capable of transporting and releasing siRNA adequately.  Nanoparticles 
provide a means of achieving this.  Peptides, lipids, and polymers are among some of the 
materials that have been used to deliver siRNA and are described below (8). 
  The smallest type of nanoparticle (about 10nm) are those where the sense strand of the 
siRNA is attached to a peptide or small molecule.  This modification of the sense strand does 
not affect the siRNA’s ability knockdown a gene, since the antisense portion of the siRNA is 
what binds to the mRNA.  Studies have shown that conjugating siRNA to CPP or PEG have 
improved in vivo siRNA transfer (8). 
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 Larger nanoparticles allow for easier modifications that can enable cell/tissue specific 
targeting, longer circulation times, and better prevention of siRNA degradation.  Cationic 
polymers, ranging from 100-300nm have been shown to form electrostatic interactions 
between the positive charges of the polymer and the negatively charged phosphate groups of 
the siRNA backbone (8). 
 Cationic lipid vectors, also ranging from 100-300nm in size, have also shown great 
promise with knocking down genes using siRNA.  Lipid nanoparticles are believed to have a 
weaker electrostatic bond with the siRNA which allows for easier release of the siRNA into the 
cytosol.  Several lipid vectors have been commercially produced to deliver siRNA to cells.  These 
include Lipofectamine RNAiMAX and DharmaFECT, as well as others (8). 
 Both cationic lipids and polymers have the complication of toxicity.  This can be avoided 
by using a neutral liposome vector, often smaller than 200 nm in size.  These nanoparticles 
often have hydrophilic cores that contain the siRNA with hydrophobic surfaces that protect the 
siRNA from degradation from the surrounding environment.  The hydrophobic surface also aids 
with internalization of the siRNA through endocytosis or membrane fusion (8). 
 Other nanoparticles include Hyaluronic acid nanoparticles, also known as nanogels, 
which have successfully targeted CD44 receptors in vitro.  Poly(d,l lactic-co-glycolic) acid (PLGA) 
nanoparticles have also been used with siRNA and have shown significant knockdown of genes 
in vivo with less inflammation in comparison to the lipid equivalents.  In addition, calcium 
carbonate nanoparticles have also shown reduced toxicity with efficacious delivery of siRNA 
both in vitro and in vivo.  Gold nanoparticles have also been shown to extend siRNA half life 
sixfold compared to naked siRNA (4). 
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 Limitations also exist for siRNA encapsulated nanoparticles.  Nanoparticle aggregation 
can occur due to the positive surface charge of the nanoparticles.  This can be addressed by 
introducing poly(ethylene glycol) (PEG) or certain sugar molecules (cyclodextrin and hyaluronic 
acid) to the reduce surface charge.  By neurtralizing the surface charge the nanoparticles will be 
capable of circulating for longer periods of time and non-specific interactions between the 
positively charged nanoparticles and the negative charge of the cell membrane will be 
minimized.  Targeting the nanoparticles to a specific tissue or cell has also been a problem with 
this delivery vector.  Modifications to the nanoparticle complex with ligands or antibodies that 
recognize specific receptors has helped with this problem.  Nanoparticles are also capable of 
entering the cell via endocytosis (1).  However, for the siRNA to be effective it must be released 
from the nanoparticle and endosome to the cytosol in order for the RISC complex to form.  
Modifications to the nanopartcle with ligands that specifically target receptors that will mediate 
endocytosis can enhance nanoparticle internalization.  Once within the endosome the 
nanoparticles must evacuate the endosome to get into the cytosol, which can be achieved by 
using polymers that contain protonable amines that are capable of disrupting the endosomal 
membrane or by using polymers that transition from hydrophilic to hydrophobic and can lyse 
the endosomal membrane.  Although methods have been used to address endosomal escape, 
new studies have shown that while 90-95% of internalized siRNA nanoparticles occurs via 
endocytosis, it is the remaining 5% that enters the cell through alternative pathways that 
provides the most functional siRNA within the cytosol (8). 
GBM targets for siRNA 
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 Nanoparticle delivery of siRNA has introduced a new means of gene therapy, however, 
finding the appropriate gene target to suppress tumor growth or induce apoptosis has been a 
difficult feat.  Identifying an appropriate marker for brain tumors and understanding its 
variations and evolutions are important.   
Epidermal growth factor receptor gene is a gene commonly found over-expressed in 
GBM and is found in about 40% of GBMs patients.  Within this population of GBM tumors that 
over-express the EGFR, 63-75% of them have rearrangements of the EGFR gene which can 
cause tumors to contain wild type EGFR as well as a mutated form.  Amongst these mutations 
the EGFR variant III, or EGFRvIII, is the most common of the mutated forms and is rarely seen in 
normal tissue.  This variant is often seen in 20-30% of GBM patients without an overexpression 
of EGFR and 50-60% of patients with an overexpression.  This mutation often results from a loss 
of exons 2 to 7 in the EGFR gene (9). 
 Type 1 interferon gamma has also shown antitumor activity, however with a short half-
life and toxicity occurring with large doses, interferon must be continuously delivered which 
increases the likelihood of toxicity.  
Research with nanoparticles and GBM 
 Within the last decade an increasing number of biodegradable polymers have been used 
against Glioblastoma Multiforme.  Chemotherapy with cisplatin was added into 6-
carboxylcellulose polymer then infused into post-irradiated patients and was found to be 
extend survival to 427.5 days compared to the control group which survived 211.0 days (10).   
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A recent Phase I/II clinical trial used CED of a liposomal vector containing the HSV-1-tk 
gene with systemic ganciclovir to treat glioblatoma.  This treatment was shown to have minimal 
side effects and showed a 50% tumor volume reduction in 25% of the treated patients (11). 
The copolymer polifeprosan 20 (1,3 bis(p-carboxyphenoxy) propane and sebacic acid in 
a 20 to 80 molar ratio with carmustine wafers (Gliadel®) have been shown to have sustained 
release for up to five days when placed in a tumor resected cavity (4).   The Gliadel wafer spans 
14mm in diameter, 1mm in thickness and is loaded with 7.7mg of carmustine.  Studies have 
shown improved survival of patients with malignant gliomas who received Gliadel either as a 
treatment for an initial tumor presentation, recurrence, or as an additional therapy with 
radiotherapy.  There have however been mixed reports about the affects of Gliadel in regards 
to toxicity, inflammation, infection rates in patients (3).  Similar to other wafers, the 
chemotherapy released by the Gliadel has relatively poor diffusion throughout the brain.  To 
resolve this issue smaller drug carrying polymers that are able to perfuse the brain parenchyma 
and deliver the chemotherapy can be used.  Among the biomaterials that have been used for 
this purpose, the copolymer poly(lactide-co-glycolide) has shown the most promise for 
delivering drugs and peptides and will be further explored in the experiments of this thesis. 
 
Statement of purpose specific hypothesis and specific aims of the thesis 
Hypothesis: 
Convection-Enhanced Delivery of siRNA-loaded Polymer Nanoparticles Produces 
Effective Gene Knockdown in gliosarcoma tumor cell both in vitro and in vivo. 
Specific Aims: 
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The goal of these experiments was to develop a new effective delivery method for 
treating tumor cells in rats.  Convection-enhanced delivery of siRNA nanoparticles can 
introduce a new means of eliminating invasive tumor cells and provide an innovative strategy 
for brain cancer treatment.  The enhanced green fluorescent protein (EGFP) transfected into 
the tumor cells allowed for good visualization of tumor growth and volume quantification after 
harvesting the brain tissue.   
This project was divided into multiple parts with specific objectives:    
The first set of experiments consisted of an in vitro analysis of the growth pattern of 
EGFP 9L gliosarcoma cells that were transfected with EGFP via lentiviral vectors, in order to 
prove consistent growth patterns between transfected and non-transfected 9L gliosarcoma 
cells.  The next set of experiments aimed to analyze the efficacy of siRNA knockdown of EGFP 
from the 9L gliosarcoma cells in vitro, using lipid vectors and PLGA vectors.  
Experiments then looked at the growth rates of 9L gliosarcoma tumor cells with 
enhanced green fluorescent protein (EGFP) in Fisher 344 rats in order to establish the in vivo 
growth rate of the tumor cells.  Once the untreated tumor cell growth curve had been 
established, small interfering enhanced green fluorescent protein (siEGFP) loaded polymer 
nanoparticles were infused into growing EGFP tumor cells using the convection-enhanced 
delivery method with the aim of determining the effectiveness of CED of nanoparticles in 
knocking down gene expression. 
 The next experiments aimed at identifying a gene within the gliosarcoma cells 
that would suppress tumor growth.  In vitro studies determined the efficacy of siRNA gene 
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knockdown and growth suppression.  Nanoparticles loaded with small interfering RNA targeting 
epidermal growth factor receptor (EGFR) were used.   
Methods 
Cell Lines 
 The 9L rat gliosarcoma cell lines where maintained in a Dulbecco's Modified Eagle 
Medium (DMEM) solution that was supplemented with 10% FBS and 1% Penicillin-
Streptomycin-Fungazone antibiotic. 
 Cells were split by removing old media and rinsing cells once with 10 mL sterile PBS.  
Trypsin EDTA 1X (.25%) was used to detach cells.  Additional media was added to the cells and 
they were centrifuged with the supernatant disgarded.  The cell pellet was then resuspended in 
fresh media and added back into a 275 mL flask.  Feeding of the cells was done daily.  The old 
media was removed and 12mL of fresh media was added to each flask.  The flasks were then 
incubated at 37◦C. 
Transfection of 9L gliosarcoma cells 
 The 9L gliosarcoma cell line was transfected with enhanced green fluorescent protein 
(EGFP) using the pSicoR plasmid (addgene©) and lentiviral vectors by Dr. Jiangbing Zhou, a 
member of Dr. Mark Saltzman’s lab. 
In vitro growth rate analysis 
 Both the normal 9L cells and EGFP transfected 9L cells were plated in 6-well plates 
(5x10^4 cells/well) with 3mL culture media per well.  Cells were extracted using trypsin and 
counted using a hemocytometer on day 2 and 3. 
Production of siRNA PLGA nanoparticles: 
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Polylactic-coglycolic acid (PLGA) were loaded with siRNA/polyamines using the double-
emulsion solvent evaporation technique.  The siRNA was reconstituted in deionized water.  The 
polyamine complexes with siRNA where formed at room temperature for 15 minutes on a 
rotary shaker.  The siRNA (30-300nmoles) was combined with the polyamine at a molar ratio of 
the polyamine nitrogen to the polynucleotide phosphate (N/P ratio of 8:1).  A molecular weight 
per nitrogen of 85g/mole of spermidine was used.  The aqueous solution was then added 
dropwise to a PLGA polymer solution and dissolved into dicholormethane (2mL) to create the 
first emulsion.  The emulsion mixture is then added dropwise into 4 mL of 5% polyvinyl alcohol 
(PVA) and sonicated to form the double emulsion.  This final emulsion was then poured into 
aqueous 0.3% (v/v) PVA and stirred for 3 hours, which allows the dicholormethane to dissolve 
and the nanoparticles to harden.  Sonication time and amplitude were optimized to formulate 
particles with 100nm diameter.  Particles were then collected by centrifugation, washed, 
rapidly frozen, and lyophilized.  The nanoparticles contained 300pmol siRNA/mg of 
nanoparticle. 
The siRNA sequences used were siEGFP, sense 5’-GGCUACGUCCAGGAGCGCACCdTdT-3’ 
and antisense 5’-UGCGCUCCUGGACGUAGCCUUdTdT-3’(MW = 14,669.4 g /mol), siEGFR sense 
5’-CCGAAUUUAUACACACCAAdTdT-3’, and antisense 5’-UUGGUGUGUAUAAAUUCGGdTdT-3’ 
(MW = 13,273 g/mol). 
Characterization of Nanoparticle size and siRNA loading 
 In order to determine the loading efficiency of the PLGA nanoparticles, 5mg of 
nanoparticles of siRNA nanoparticles were dissolved in 0.5mL of dichloromethane at room 
temperature for 30 minutes.  The nanoparticles were extracted from the organic phase using 
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0.5mL TE buffer (10mM Tris-HCl, 1mM EDTA, pH 7.4).  The TE buffer was added to the organic 
phase and vortexed for 1 minutes, and then centrifuged at 12,000 rpm for 5 min at 4◦C. The 
combined 1 mL aqueous fraction was analyzed for double-stranded RNA content using the 
QuantIT™PicoGreen™ assay (Invitrogen).  A standard curve relating fluorenscence to siRNA 
concentration was used to determine the amount of siRNA in the nanoparticles. 
 Particle size was determined using the dynamic light scattering (DLS) feature of the 
ZetaPals (Brookhaven Instruments) particle size analyzer.  Particles were analyzed in a 10μg/mL 
in 2mL PBS solution.  The particle size was also analyzed using an image analysis of micrographs 
from a scanning electron microscopy (SEM).  The samples were coated with 25 nm-thick gold 
using a quick carbon coater.  Using image analysis software the particle diameter and size 
distribution was determined. 
Nanoparticle Delivery to Cultured Cells 
Cells were plated at 3x10^4 to 5x10^4 cells per well in a 6-well tissue culture treated 
plate and left to proliferate.  After 48 hours in culture, cells were at 30-50% confluence.  
Nanoparticle treatment groups and controls were diluted in the DMEM solution with 
supplements at a concentration of .1mg/mL for the particles.  Cells were exposed to 10nM-
25μM of siRNA.  The treatment groups included siRNA-loaded PLGA nanoparticles, siRNA-
loaded lipid nanoparticles, a control with no siRNA.  Treatment groups were placed on the cells 
in 100μL volumes and left for 48, 72, and 120 hours at 37C and 5% CO2.  At the end of 
incubation, the cells were washed with PBS.  Cells were then extracted using trypsin and 
evaluated using FACS or RT-PCR. 
FACS analysis 
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The LSR II Green (BD Biosciences) multilaser multiparameter analysis was utilized.  The 
digital data collection was done using the FACS DIVA software.  The 488nm (blue) detector was 
used to identify the GFP fluorescence.  Round bottom 12 x 75 mm polystyrene falcon tubes 
were used.  Cells were extracted and resuspended in 1mL of PBS supplemented with 10% fetal 
calf serum (FCS), 1% sodium azide. 
RT-PCR 
RNA was isolated from the 9L gliosarcoma cells using the RNeasy®Mini Kit (Qiagen) 
based on the manufacturer’s protocol.  The purified mRNA was reverse transcribed using the 
iScript DNA synthesis kit (Biorad) to produce cDNA.  Real time PCR was conducted on 2μL of 
cDNA combined with the iQ SyBr Green (biorad) reagents for fluorenscent detection of the PCR 
product.  Primers used for the RT-PCR are: EGFP_forward: 5’- GAAGCGCGATCACATGGT – 3’, 
EGFP_reverse: 5’-CCATGCCGAGAGTGATCC-3’.  PCR parameters consisted of 5 minute activation 
of the DNA polymerase at 95◦C, followed by 40 cycles of expression of 95◦C x 20 s, 60◦C x 30 s, 
and 72◦C x 20s. 
Implanting tumors in Rat Brain Tissue 
The glioma tumor cell line that was used in these experiments were 9L gliosarcoma cells.  
These cells induced intracerebral tumors via a craniotomy and using stereotaxis to determine 
the injection locations in the brain.   
During the surgery the rodents received pre-procedural anesthetic intraperitoneal 
injections of ketamine/xyalzine mixture (80/10 mg/kg), followed by an intraperitoneal 
analgesic, meloxicam at 0.3 -1.0 mg/mg.  Once anesthetized, the scalp of the rodent was 
shaved using clippers, and the scalp was sterilized using alcohol and betadine wipes.  The 
25 
 
animal was restrained on a stereotaxic frame, which held the animal in place using two ear bars 
and a nose bar.  Heart rate and respiratory rate of the animal were monitored manually during 
the surgery.  These intracranial surgeries took approximately 30 minutes per rat.  A midline 
incision was made along the scalp using a scalpel.  The pericranium was pushed aside and 
excess bleeding was wiped off using q-tips until the coronal and sagittal sutures were exposed.  
Once the injection coordinates are identified, a burr hole was drilled into the skull going -
3.5mm posteriorly and 2.3mm laterally to the right from bregma using a high speed drill.  A 
sterile needle punctured the dura and a Hamilton syringe was filled with 1.5µl (1.5x105 cells) of 
EGFP-labeled 9L gliosarcoma cells suspended in injection buffer (sterile PBS, MgCl2 (1µg/mL), 
CaCl2 (1ug/mL), 0.1% glucose).  The needle was inserted 5.7mm deep into the cerebral cortex 
and allowed to equilibrate for one minute in the tissue.  The needle was withdrawn about 
0.2mm and allowed to equilibrate in order to give a space for the cells to fill.  The cells were 
slowly injected (1.5µl in 1.5mins) into the tissue and given two minutes to settle before the 
syringe was removed.  The burr hole was plugged with bone wax, and the incision was sutured 
or stapled.   
Following surgery the animal was then taken to a recovery cage with food and ibuprofen 
in drinking water for 48 hours after the surgery.  The animal was monitored daily for signs of 
pain, discomfort, or abnormal movement or behavior.  The incision was checked and cleaned if 
necessary.   
Animal Maintenance 
Fischer 344 rats were used as a model system for this project because of they were large 
enough to allow intracranial implantation of polymers of sizes that fall in the range of the 
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nanoparticles that were used for these experiments.  The rats weighed 180-220 grams.  Animals 
were housed in Yale Animal Resources Center (YARC) facilities (Malone Engineering Center) and 
received the standard care.  
Harvesting of Tissue and Growth Analysis 
Following tumor implantation, animals were maintained for various amounts of time: 1-
15 days.  Animals were euthanized by carbon dioxide overdose according to YARC procedure, 
and the brain was removed and frozen directly on dry ice.  The brain was then stored in a -80◦C 
freezer before sectioning.  The brains were sectioned into thin slices of known thickness by a 
microtome machine and then fluorescent images were taken of the coronal brain sections.  The 
tumor showed up as a green image because of the EGFP, and the tumor volume was calculated 
from the area of green signal found on each slice and the given width of the slice.  
Intracranial implantation of siRNA nanoparticles 
The infusion procedure of the nanoparticles utilized convection enhanced delivery and 
was the same as the ‘Implanting tumors in Rat Brain Tissue’ procedure with a few alterations.  A 
nose cone was added to the stereotaxis frame and 1-4% of isoflurane was added to the oxygen 
to maintain anesthesia for the longer procedure.  The CED technique took longer because the 
infusion time and volume of nanoparticles infused (about 20ul) was large.  A catheter probe 
was used to administer the nanoparticles and fluid into the brain tissue, substituting for the 
Hamilton syringe.  The nanoparticles were re-suspended in 20μL sterile PBS buffer solution 
(supplemented with MgCl2 (1ug/mL), CaCl2 (1ug/mL), 0.1% glucose).  A sterile needle was used 
to puncture the dura and a syringe with the catheter probe was filled with the suspended 
nanoparticles.  The probe was then inserted into the right hemisphere of the cerebral cortex, 
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just anterior to the putamen for one minute to equilibrate with the tissue.  The nanoparticles 
were slowly injected (1.5µl in 1.5mins) into the tissue and given two minutes to settle before 
the probe was removed.  The burr hole was plugged with bone wax, and the incision was 
stapled.  Typical surgeries took about one hour per animal.   
Production of the Lipid nanoparticles 
 The siRNA was incubated with Lipofectamine™, a cationic lipid, in order to form a lipid 
complex that was infused into the brain tumor.  Established protocols for this procedure are 
available at www.invitrogen.com/RNAiMAX.  
Statistical Analysis 
 Experimental conditions were compared using a two tailed t-test to evaluate whether a 
significant difference existed between conditions.  P-values less than 0.05 were considered to 
be significant.   
The PLGA and Lipid nanoparticle conditions were corrected with their respective 
controls in the in vivo charts.   
All experiments were conducted by the author unless otherwise stated. 
 Tumor fluorescent volume is a term used in this thesis that refers to the overall 
fluorescence generated by the 9L gliosarcoma cells.  When exposed to small interfering EGFP 
(siEGFP), the actual tumor cell volume 
remains unchanged, but the siEGFP 
exposed tumor cells have a lower tumor 
fluorescent volume (Figure 1).  
 
Figure 1: A, represents a group of EGFP transfected 9L gliosarcoma 
cells that have not been exposed to siEGFP, while B, represents a 
group of EGFP transfected 9L gliosarcoma cells after exposure to 
siEGFP.  Specimen A and B have equal overall tumor volume, but 
specimen A has a higher tumor fluorescent volume than specimen 
B. 
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Figure 2: The EGFP transfected 9L 
gliosarcoma cells show a similar growth 
patterns as a non-transfected 9L gliosarcoma 
cells over a three day period.  The p-value for 
both timepoints was p>0.05 
 
Results 
EGFP transfected cell proliferation assay  
 A proliferation assay compared regular 9L 
gliosarcoma passage 5 cells to 9L passage 5 cells that 
were transfected with EGFP with a lentiviral vector 
in order to determine whether the transfected cells 
had a similar growth rate as the regular cells.  On 
day two the transfected 9L cells showed a similar 
growth rate to the normal 9L cells with the 
standardized mean cell count being 9 ±2.2 and 10.1 
±2.1 respectively (Figure 2).  The two tailed t-test showed a p-value of 0.68.  The day three time 
points of the transfected cells showed a mean standardized cell growth of 18.6 ±2.9 and the 
normal 9L cells showed a mean of 22.6 ±3.1.  The two tailed t-test showed a p-value of 0.13 
(n=3). 
Characterization of the siRNA 
The PLGA nanoparticles loaded with siEGFP or siEGFR were analyzed by scanning 
electron microscopy and dynamic light scattering to characterize the size.  The data generated 
from the DLS was used to create a histogram to calculate the average diameter of the 
nanoparticles.  For the siEGFP-loaded PLGA nanoparticles the mean diameter was 110 ±24nm 
(n=100).  The minimum and maximum diameters were 58.7 and 182.7 nm.  This was supported 
by the SEM analysis.   The histogram of the siEGFR-loaded nanoparticles showed nanoparticles 
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with a mean diameter of 109 ±20nm (n=103).  The minimum and maximum diameters were 
73.6nm and 176.5nm, respectively (Figure 3).  The SEM confirms the size of the nanoparticles. 
In vitro siRNA nanoparticle knockdown 
An in vitro study was conducted that looked at the efficacy of siRNA knockdown of the 
EGFP using the PLGA nanoparticles.  The EGFP transfected 9L gliosarcoma cells were plated on 
6-well plates and exposed to three conditions: siEGFP-loaded PLGA nanoparticles, scrambled 
siRNA PLGA nanoparticles, and no nanoparticles.  The cells were exposed to 10nM of siRNA 
within the nanoparticles.  Over a four day period the siEGFP-loaded nanoparticles showed 
significant knockdown under visual microscopy.  The PLGA nanoparticles with scrambled siRNA 
Figure 3: Top left, scanning electron micrographs (SEM) of the siEGFP nanoparticles prepared using spermidine as a complexing agent. 
Top right, histogram of siEGFP-loaded PLGA nanoparticle diameters with a mean value of 110 ±24nm.  Bottom left, SEM image of the 
siEGFR nanoparticles.  Bottom right, histogram depicting the diameters of siEGFR-loaded PLGA with a mean value of 109 ±20nm. Bar = 
500nm.  
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showed minimal knockdown (Figure 4).  FACS and RT-PCR were used to quantify the level of 
fluorescence generated from the cells at the three time points (Figure 5).  The FACS analysis 
showed the siEGFP-loaded nanoparticles were capable of diminishing the majority of the 9L 
population fluorescence () and possessed a small population of complete knockdown ().  
The RT-PCR analysis looking at the level of EGFP expression showed a 45% 
green fluorescent reduction by the siEGFP compared to the control on day two.  The scrambled 
siRNA nanoparticles had no significant difference in the level of fluorescence compared to the 
control (p=0.79, n=6).  On day 3, the siEGFP reduced fluorescence by 53% compared to the 
control.  The scrambled siRNA nanoparticles had no significant difference in the level of 
fluorescence (p=0.06).  Day 5 results were similar with the siEGFP-loaded nanoparticle 
condition showing a 50% EGFP expression reduction and the scrambled siRNA had no significant 
EGFP reduction compared to the control (p=0.07). 
Figure 4: In vitro images 
of the enhanced green 
fluorescent protein 9L 
gliosarcoma cells that 
were grown to 30% 
confluency and were then 
exposed to the siRNA 
nanoparticles for three 
different timepoints.   
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In vivo 9L EGFP gliosarcoma cell knockdown 
The Fischer 344 rats were intracranially injected with 9L gliosarcoma cells which were 
allowed to grow for five days.  On day 5, either lipid or PLGA nanoparticles were injected 
intratumorally and tumor fluorescent growth was analyzed on day 8, 11, and 15 (Figure 6).  On 
day 8, the siEGFP-loaded PLGA nanoparticles showed significant knockdown of the EGFP 
fluorescence, in vivo, with a 60% reduction of the fluorescence (p-value= 0.009, n= 3).  The 
mean tumor fluorescent volume of the 9L cells exposed to siEGFP-loaded nanoparticles were 
3.8±1.6mm3 compared to the control which was 9.6±2.9mm3.  The siEGFP-loaded lipofectamine 
also showed some EGFP knockdown with a tumor fluorescent volume of 6.7±4.4mm3 (p-value = 
0.03, n= 3).  Compared to the lipid nanoparticles, the siEFGP-loaded PLGA nanoparticles 
showed 30% more reduction of the 9L cells green fluorescence than the lipid vectors (p-value = 
Figure 5: Nanoparticles delivering siEGFP are internalized and cause sustained gene silencing in cultured cells, in 
vitro. A, FACS analysis shows EGFP expression was reduced in cultured cells exposed to the siEGFP nanoparticles () 
and a small population showed complete knockdown ().  B, RT-PCR  results of the siEGFP nanoparticles knockdown 
on cultured cells.  The * mark is above the bar for the normal 9L cells EGFP expression (n=3). 
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Figure 5: The Fischer 344 rats were injected with 9L gliosarcoma cells which were allowed to grow in vivo for 5 days.  
Nanoparticles (either lipid or PLGA) were injected into the rat brain, intratumorally, on day five and remained in the 
brain for an additional three, six, or ten days.  The rats were sacrificed and the brain was harvested and cut into 
coronal sections.  The cells exposed to the siEGFP had various levels of green fluorescent knockdown.  A microscope 
was used to analyzed the total tumor fluorescent volume. 
 0.04).  On day 11 however the tumor fluorescent volumes showed no significant difference with 
the siEGFP-loaded PLGA nanoparticles (p-value = 0.26) and the siEGFP-loaded lipid 
nanoparticles (p-value = 0.13) compared to the control.  Day 15 showed similar results with the 
no tumor fluorescent volume difference with the siEGFP-loaded PLGA nanoparticles (p-value = 
0.75) and siEGFP-loaded lipid nanoparticles (p-value = 0.11) (Figure 7).   
In vitro knockdown of 9L gliosarcoma cell growth 
 A gene target capable of suppressing growth of 9L gliosarcoma cells was identified to 
test out the knockdown capabilities of siRNA nanoparticles.  Epidermal growth factor receptor 
gene was the target for siRNA knockdown.  Small interfering epidermal growth factor receptor 
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(siEGFR) was encapsulated by PLGA.  In addition, nonspecific siRNA (scrambled siRNA) was also 
encapsulated in PLGA.   The 9L cells were plated on 6 well plates and grown for 48 hours.  At 
this time the cells were exposed to the siEGFR or scrambled siRNA nanoparticles.  Two days 
after exposure to the siEGFR significant suppression of growth was seen in the the 9L 
gliosarcoma cells with a 66 percent reduction of growth (p value =0.048, n = 3).  The scrambled 
siRNA did not show any significant suppression of the 9L growth (p value = 0.21, n = 3).  Three 
days after siRNA exposure, the siEGFR showed an 89 percent reduction of growth compared to 
the control (p value= 0.022).  The scrambled siRNA did not show any growth suppression (p-
value = 0.32) (Figure 8,9).  Time constraints prevented an in vivo study of the effects of siEGFR-
loaded nanoparticles on 9L cells from being conducted. 
Discussion 
The reported experiments explored the efficacy of siRNA nanoparticles both in vitro and 
in vivo.  The EGFP transfected 9L gliosarcoma cells were shown to have consistent growth with 
Figure 7: A, Day 8 of the in vivo Tumor fluorescent volume.  The siEGFP-loaded PLGA nanoparticles (25nM) showed 
significant green fluorescent knockdown (p=0.009).  The lipid nanoparticles also show significant tumor fluorescent 
reduction (p=0.03). B, Day 11 and 15, showed no significant difference in fluorescence compared to the control. 
 
34 
 
the normal 9L cells and proved to serve as an adequate tumor cell model for the analysis of the 
efficacy of siRNA knockdown.  The proliferation analysis showed no significant difference 
between the growth rate of the 9L transfected cells compared to the non-transfected cells, 
which allowed the green fluorescent transfected cells to be used for growth assessment 
studies. 
 Both the small interfering enhanced green fluorescent protein (siEGFP) and the small 
interfering epidermal growth factor receptor (siEGFR) were able to encapsulate into a PLGA 
copolymer with a diameter of around 110nm.  Although the extracellular space fluid filled pores 
in a Fischer 344 rat are around 38-64nm diameter and optimal nanoparticle diffusion within the 
rat brain would require a diameter within this range, with the pressure from the convection 
enhanced delivery and the particles’ distribution origin starting from within the tumor, the 
nanoparticles were still capable of diffusing (12). 
Figure 8: Microscopic images of 9L gliosarcoma cells after exposure to siEGFR and scrambled siRNA.  The siEGFR 
reduced the growth of the 9L cells by 66% two days after exposure and 89% three days after.  The scrambled siRNA 
showed no significant growth reduction. 
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Figure 9: 9L gliosarcoma cells 
were plate on 6-well plates and 
allowed to grow for 24 hours and 
then exposed to siEGFR and 
scrambled siRNA nanoparticles.  
Two days after exposure to the 
siRNA the siEGFR showed 
significant suppression of 9L 
growth (p=0.048) while the 
scrambled siRNA did not 
(p=0.21).  Day 4 showed a 89% 
growth reduction of the siEGFR 
condition compared to the 
control (p=0.022). (The 
scrambled siRNA contained small 
interfering enhanced green 
fluorescent protein, siEGFP). 
 In vitro studies of the siEGFP nanoparticle knockdown compared to the control and 
scrambled siRNA showed significant knockdown of the green fluorescent signal over a five day 
period.  The FACS and RT-PCR studies determined that the majority of EGFP transfected 9L 
gliosarcoma cells had underwent a significant reduction in green fluorescence, however only a 
small population of cells had underwent complete knockdown.  The small number of complete 
knockdown cells could be indicated by the low concentration (10nm) of siEGFP that was used in 
the in vitro studies.  
 In vivo studies produced similar results as the in vitro study, showing significant 
knockdown of the green fluorescence with siEGFP-loaded PLGA nanoparticles.  The PLGA 
nanoparticles were compared to lipid nanoparticles which have been shown to have efficacious 
siRNA delivery capability, however are considered to be neurotoxic (13).  Three days following 
in vivo exposure of the 9L tumor to siEGFP-loaded PLGA nanoparticles, there was a significant 
knockdown compared to both the control and the lipid nanoparticles.  The sixty percent green 
fluorescent reduction by the siEGFP-loaded PLGA nanoparticles showed that the siRNA as a 
drug delivery mechanism has potential of suppressing gene expression with specificity.  
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However, at six and ten days following in vivo introduction of the siRNA, the PLGA polymers did 
not show any significant knockdown of the EGFP in the 9L cells.  Similar to the in vitro studies, 
the nanoparticles were likely to not contain a large enough dose of the siEGFP.  Loading PLGA 
nanoparticles with siRNA has been shown to be difficult and often results in nanoparticles with 
low siRNA concentration (14).  Using the common preparation technique of the double 
emulsion solvent evaporation method, it is difficult to have a high siRNA loading efficiency.  This 
is a result of the low molecular weight of the siRNA which allows for the nuclei acid to leak out 
of the inner water phase of the nanoparticle into the environmental outer water phase during 
the preparation.  The hydrophilic nature of the siRNA along with the electrostatic repulsion 
forces of the phosphate groups of the nucleic acid and the anionic acid groups of the polymer 
causes the siRNA to leak out.  This makes it difficult to have high encapsulation efficiency and 
causes quick release of the siRNA once it is exposed to the hydrophilic environment, which may 
be the cause of the early fluorescent knock down, but no subsequent knock down in the 
following timepoints.  
 Strategies to address this issue might be to change the spermidine complexing agent to 
another cationic material such as dioleyltrimethylammoniumpropane (DOTAP) or 
polyethyleneimine which have stronger bonds to siRNA.  However, these materials may delay 
the release of siRNA. 
 With evidence of efficacious gene suppression of the green fluorescence in the 9L cells, 
the next experiments looked at a gene target that would suppress cellular proliferation.  Small 
interfering epidermal growth factor receptor (siEGFR) was selected for in vitro studies and 
showed significant suppression of cellular growth.   
37 
 
EGFR has been shown to be present in 40% of Glioblastoma patients and has been 
shown to be a viable target for growth suppression.  Although only a portion of GBM patients 
over express the epidermal growth factor receptor on their cell surface, intracellular EGFR 
affects signal transduction cascades, such as the MAPK, Akt, and JNK pathways all which are 
involved in DNA synthesis, cellular proliferation, and cell adhesion.  The intracellular activity of 
the siEGFR may offer additional suppressive effects that extend beyond solely inhibiting the 
receptor function on the outer cell surface, however no studies have determined whether 
siEGFR may inhibit intracellular transduction cascades integral to cellular proliferation in tumor 
cells that do not over express epidermal growth factor receptors.   
Although this study showed that suppression of the EGFR gene inhibits growth, new 
studies have shown that the deletion of the nuclear factor of K-light polypeptide gene enhancer 
in B–cells inhibitor-α (NFKB/A), a gene whose product functions to inhibit EGFR, can cause 
tumorigenesis in patients who lack the excessive EGFR activation that is commonly seen in a 
portion of GBM patients (15).  It is believed that this mutation in addition to the over 
expression of EGFR may represent a majority of GBM patients and provides a new potential 
gene to investigate. 
 The experimental results showed that PLGA delivery of siRNA is capable of gene 
knockdown, however the short term duration of suppression requires that additional work 
needs to be done to reduce the diameter of the PLGA nanoparticles to a size under 70nm 
where the nanoparticles may diffuse through the extracellular space of the brain with less 
obstruction.  In addition to reducing the size, utilizing different complexing agents that may be 
capable of preventing quick leakage of siRNA out of the nanoparticle may also be warranted. 
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 EGFR has been shown to be a viable gene target for growth suppression, however future 
studies using a mixture of many siRNA gene targets within the nanoparticles may provide a 
more effective suppression of growth.  Additional work will also need to investigate whether 
siEGFR has suppressive effects on 9L cells in vivo. 
The last decade has seen numerous advancements in the use of siRNA and nanoparticles 
as therapeutics for gene silencing.  Delivery of siRNA using the PLGA matrix allows for efficient 
tumor and brain penetration as well as good cellular uptake, protection of the siRNA from 
RNase activity, and an alterable and controllable degradation character that can allow for 
specific targeting and sustained release.  PLGA is a delivery vector that has shown itself to be 
efficacious with in vitro and in vivo delivery of siRNA and may provide the means of effectively 
treating brain tumors. 
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